Publikationen von H. Daub

Wissing, J.; Jansch, L.; Nimtz, M.; Dieterich, G.; Hornberger, R.; Keri, G.; Wehland, J.; Daub, H.: Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Molecular & Cellular Proteomics 6 (3), S. 537 - 547 (2007)

Reinl, T.; Wissing, J.; Fischer, R.; Hundertmark, C.; Klawonn, F.; Daub, H.; Wehland, J.; Jansch, L.: Quantitative analysis of receptor tyrosine kinase signaling exploited by Listeria monocytogenes. Molecular & Cellular Proteomics 5 (10 Suppl. Suppl. S), S. S168 - S168 (2006)

Keri, G.; Orfi, L.; Eros, D.; Hegymegi-Barakonyi, B.; Szantai-Kis, C.; Horvath, Z.; Waczek, F.; Marosfalvi, J.; Szabadkai, I.; Pato, J. et al.; Greff, Z.; Hafenbradl, D.; Daub, H.; Muller, G.; Klebl, B.; Ullrich, A.: Signal transduction therapy with rationally designed kinase inhibitors. Current Signal Transduction Therapy 1 (1), S. 67 - 95 (2006)

Daub, H.: Characterisation of kinase-selective inhibitors by chemical proteomics. Biochimica et Biophysica Acta-Proteins and Proteomics 1754 (1-2), S. 183 - 190 (2005)

Godl, K.; Gruss, O. J.; Eickhoff, J.; Wissing, J.; Blencke, S.; Weber, M.; Degen, H.; Brehmer, D.; Orfi, L.; Horvath, Z. et al.; Keri, G.; Muller, S.; Cotten, M.; Ullrich, A.; Daub, H.: Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Research 65 (15), S. 6919 - 6926 (2005)

Daub, H.; Specht, K.; Ullrich, A.: Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Reviews Drug Discovery 3 (12), S. 1001 - 1010 (2004)

Blencke, S.; Zech, B.; Engkvist, O.; Greff, Z.; Orfi, L.; Horvath, Z.; Keri, G.; Ullrich, A.; Daub, H.: Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chemistry & Biology 11 (5), S. 691 - 701 (2004)

Blencke, S.; Ullrich, A.; Daub, H.: Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. Journal of Biological Chemistry 278 (17), S. 15435 - 15440 (2003)

Daub, H.; Blencke, S.; Habenberger, P.; Kurtenbach, A.; Dennenmoser, J.; Wissing, J.; Ullrich, A.; Cotten, M.: Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. Journal of Virology 76 (16), S. 8124 - 8137 (2002)

Schaab, C.; Oppermann, F.; Pfeifer, H.; Klammer, M.; Tebbe, A.; Oellerich, T.; Krauter, J.; Levis, M. J.; Perl, A. E.; Daub, H. et al.; Steffen, B.; Godl, K.; Serve, H.: Global Phosphoproteome Analysis of AML Bone Marrow Reveals Predictive Markers for the Treatment with AC220. In BLOOD, 120 (21), 786. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta, GA, 08. Dezember 2012 - 11. Dezember 2012. AMER SOC HEMATOLOGY, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA (2012)

Daub, H.: Analysis of protein kinases by chemical proteomics. Habilitation, Technische Universität, München (2010)